Cargando…

Liver transplantation for hepatocellular carcinoma: Where do we stand?

Hepatocellular carcinoma represents an important cause of morbidity and mortality worldwide. It is the sixth most common cancer and the fourth leading cause of cancer death. Liver transplantation is a key tool for the treatment of this disease in human therefore hepatocellular carcinoma is increasin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santopaolo, Francesco, Lenci, Ilaria, Milana, Martina, Manzia, Tommaso Maria, Baiocchi, Leonardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2019
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558441/ https://www.ncbi.nlm.nih.gov/pubmed/31210712 http://dx.doi.org/10.3748/wjg.v25.i21.2591

Ejemplares similares

Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?
por: Lenci, Ilaria, et al.
Publicado: (2020)

COVID-19 in normal, diseased and transplanted liver
por: Signorello, Alessandro, et al.
Publicado: (2021)

Natremia and liver transplantation: The right amount of salt for a good recipe
por: Lenci, Ilaria, et al.
Publicado: (2020)

Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2021)

Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021)

Gastrointestinal endoscopy in cirrhotic patient: Issues on the table
por: Grassi, Giuseppe, et al.
Publicado: (2021)

Secondary bile acids and the biliary epithelia: The good and the bad
por: Lenci, Ilaria, et al.
Publicado: (2023)

Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?
por: Saraireh, Hamzeh A, et al.
Publicado: (2017)

Sequence of events leading to primary biliary cholangitis
por: Lenci, Ilaria, et al.
Publicado: (2023)

Chronic rejection after liver transplantation: Opening the Pandora’s box
por: Angelico, Roberta, et al.
Publicado: (2021)

Hepatitis C virus micro-elimination: Where do we stand?
por: Mangia, Alessandra, et al.
Publicado: (2021)

Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?
por: Galanopoulos, Michail, et al.
Publicado: (2018)

De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature
por: Manzia, Tommaso Maria, et al.
Publicado: (2019)

Relationship between GH/IGF-1 Axis, Graft Recovery, and Early Survival in Patients Undergoing Liver Transplantation
por: Salso, Angela, et al.
Publicado: (2014)

Renal Function, Adherence and Quality of Life Improvement After Conversion From Immediate to Prolonged-Release Tacrolimus in Liver Transplantation: Prospective Ten-Year Follow-Up Study
por: Toti, Luca, et al.
Publicado: (2022)

Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?
por: Bartolotta, Tommaso Vincenzo, et al.
Publicado: (2019)

Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2018)

Hepatocellular Carcinoma in Pakistan: Where do We Stand?
por: Butt, Amna Subhan, et al.
Publicado: (2012)

Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do
por: Sanchez-Torrijos, Yolanda, et al.
Publicado: (2017)

Defining the Pseudomonas Genus: Where Do We Draw the Line with Azotobacter?
por: Özen, Asli I., et al.
Publicado: (2011)

Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
por: Russo, Francesco Paolo, et al.
Publicado: (2022)

Where Do We Stand?
Publicado: (1891)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Artificial intelligence and inflammatory bowel disease: Where are we going?
por: Da Rio, Leonardo, et al.
Publicado: (2023)

Mergers with Differentiated Products: Where Do We Stand?
por: Valletti, Tommaso, et al.
Publicado: (2021)

Sessile serrated adenoma/polyps: Where are we at in 2016?
por: Singh, Rajvinder, et al.
Publicado: (2016)

Face Transplant: Indications, Outcomes, and Ethical Issues—Where Do We Stand?
por: La Padula, Simone, et al.
Publicado: (2022)

COVID-19 and liver injury: where do we stand?
por: Papadopoulos, Nikolaos, et al.
Publicado: (2020)

Assessment of Liver Function With MRI: Where Do We Stand?
por: Río Bártulos, Carolina, et al.
Publicado: (2022)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Hepatocellular Carcinoma (HCC), Where do we stand? Current situation
por: Hafeez, Muhammad, et al.
Publicado: (2020)

Endoscopic therapy for Barrett’s esophagus and early esophageal cancer: Where do we go from here?
por: Singh, Tavankit, et al.
Publicado: (2018)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Nanotherapeutics in transplantation: How do we get to clinical implementation?
por: Plumblee, Leah, et al.
Publicado: (2022)

Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature
por: Ghosn, Marwan, et al.
Publicado: (2016)

Moving forward in the treatment of cholangiocarcinoma
por: Manzia, Tommaso M, et al.
Publicado: (2021)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Anesthesiology and the Difficult Airway – Where Do We Currently Stand?
por: Richtsfeld, Martina, et al.
Publicado: (2017)

Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading?
por: Daoud, Ahmed, et al.
Publicado: (2021)

Thrombocytopenia after liver transplantation: Should we care?
por: Takahashi, Kazuhiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1u9snde8fgt4cdlmqnsnq0hdbd